We recently identified that transcription factor SP1 is an inhibitor for USP22 gene expression [38], and here we found that FT671 treatment induced a significant decrease of SP1 protein in both A549 and H1299 cancer cells (Fig. 2C). Here, USP22 is linked to cancer.